Regulation is complex, but it’s forcing clarity
The Packaging and Packaging Waste Regulation (PPWR) is reshaping how the whole packaging sector thinks about materials, and pharmaceutical packaging is no exception. But the regulation is causing significant confusion across the value chain and the most common question I hear is a fundamental one: is pharma packaging exempt?
The answer isn't straightforward. For example, specific derogations from the Design for Recycling (DfR) requirements exist for the immediate packaging of medicinal products until 2035 and for the recycled content targets regarding contact-sensitive plastic packaging of medical devices. But not every pharmaceutical package qualifies for such exemptions. If the outer packaging isn't required to preserve product quality, the DfR and recycled content requirements apply.
Take a nasal spray sold in a cardboard box. The HDPE spray itself appears to meet the criteria for a derogation. The cardboard box is unlikely to qualify for an exemption from the DfR requirements since it is not necessary to preserve the quality of the product. However, it is exempted from the recycled content targets since those currently focus on plastic components. That's a small distinction with significant commercial implications — and it's the kind of detail that gets missed when companies assume a blanket exemption.
PPWR is pushing the industry toward decisions it might otherwise have deferred. In that sense, the regulatory pressure and the sustainability agenda are pointing in the same direction, which is useful, even if navigating the details is genuinely complex.
The digital layer could reshape everything
When I think about what will genuinely change pharmaceutical packaging in the next three to five years, I keep coming back to the same answer: not a new material, but a new layer of intelligence. RFID and NFC are moving from pilot to mainstream and the implications go well beyond track-and-trace.
On the manufacturing side, RFID helps tackle what I’d describe as a hidden waste problem. 2022 research suggests that around 4% of pharmaceutical production is currently lost to batch mix-ups, expired product and resource misallocation. Real-time tracking can significantly reduce that waste while improving efficiency across the process.
At end of life, NFC opens up different possibilities. With packaging like autoinjectors, where emissions are heavily driven by raw materials and disposal, NFC can support electronic product information, authentication, adherence tracking and recycling guidance without changing the physical container itself.
The challenge is making these solutions work consistently across packaging lines, markets and regulatory frameworks. That’s where testing and collaboration across the value chain become essential. What’s becoming clearer is that sustainability and patient safety are starting to align. Less waste, greater traceability and smarter end-of-life systems all contribute to more reliable pharmaceutical packaging.
